Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (MABs, Recombinant Protein), By Indication (Oncology, CVDs), By Region, And Segment Forecasts, 2025 - 2030
Biologics Contract Manufacturing Market Growth & Trends
The global biologics contract manufacturing market size is expected to reach USD 57.59 billion by 2030, registering a CAGR of 10.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The global market was growing efficiently during the COVID-19 pandemic. This is due to a rise in R&D activities for the development of COVID-19 vaccines. In addition, there has been an expansion in manufacturing facilities to control the spread of the disease. For instance, in November 2021, Lonza announced that it has decided to expand its microbial development laboratories in Switzerland to support the company’s upcoming projects.
It is believed that post-pandemic there will be numerous fundamental changes. There will be an increase in the production and manufacturing efforts for the development of vaccines and therapeutics against the coronavirus and a rise in digital capabilities across all their operating units. These initiatives will help them in joint planning with pharma clients in building more strategic partnerships. For instance, in January 2022, Lonza launched a technology that will be used for the discovery and design of antibodies that are biospecific and this technology will be called bYlok™. The outsourcing of drugs or biologics manufacturing is rapidly increasing around the world.
Pharmaceutical and biotechnology companies concentrate on their core projects while reducing the operational costs associated with manufacturing drugs or biologics. Contract Manufacturing Organizations (CMOs) are specialized and experienced in conducting the entire process of manufacturing. In-house manufacturing of biologics is difficult as it is a complex process and involves many resources. CMOs link the demand and supply gap by focusing on improving the drug discovery process resulting in faster availability of biologics for patients. Hence, due to these factors, outsourcing activities are rapidly increasing.
Biologics Contract Manufacturing Market Report Highlights
- Based on products, the MABs segment accounted for the largest revenue share in 2024 as MABs are used in the treatment of a wide range of diseases, such as cancer, infectious diseases, asthma, and auto-immune diseases
- Based on indications, the oncology segment dominated the market in 2024 with the largest revenue share. The main factor responsible for the high segment share is the increased number of cancer cases
- North America dominated the global market in 2024 due to the increased outsourcing services for manufacturing drugs & biologics and high R&D expenditure in the region
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Indication
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Biologics Contract Manufacturing Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- Chapter 4. Biologics Contract Manufacturing Market: Product Business Analysis
- 4.1. Product Market Share, 2024 & 2030
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.4. Monoclonal Antibodies (mAbs)
- 4.4.1. Monoclonal Antibodies (mAbs) Market, 2018 - 2030 (USD Million)
- 4.5. Recombinant Proteins
- 4.5.1. Recombinant Proteins Market, 2018 - 2030 (USD Million)
- 4.6. Vaccines
- 4.6.1. Vaccines Market, 2018 - 2030 (USD Million)
- 4.7. Antisense, RNAi, & Molecular Therapy
- 4.7.1. Antisense, RNAi, & Molecular Therapy Market, 2018 - 2030 (USD Million)
- 4.8. Others
- 4.8.1. Others Market, 2018 - 2030 (USD Million)
- Chapter 5. Biologics contract manufacturing Market: Indication Business Analysis
- 5.1. Indication Market Share, 2024 & 2030
- 5.2. Indication Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
- 5.4. Oncology
- 5.4.1. Oncology Market, 2018 - 2030 (USD Million)
- 5.5. Autoimmune Diseases
- 5.5.1. Autoimmune Diseases Market, 2018 - 2030 (USD Million)
- 5.6. Infectious Diseases
- 5.6.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
- 5.7. Cardiovascular Diseases
- 5.7.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
- 5.8. Metabolic Diseases
- 5.8.1. Metabolic Diseases Market, 2018 - 2030 (USD Million)
- 5.9. Neurology
- 5.9.1. Neurology Market, 2018 - 2030 (USD Million)
- 5.10. Others
- 5.10.1. Others Market, 2018 - 2030 (USD Million)
- Chapter 6. Biologics Contract Manufacturing Market: Regional Estimates & Trend Analysis by Product and Indication
- 6.1. Regional Market Share Analysis, 2024 & 2030
- 6.2. Regional Market Dashboard
- 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
- 6.4. North America
- 6.4.1. North America Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 6.4.2. U.S.
- 6.4.2.1. Key Country Dynamics
- 6.4.2.2. Regulatory Framework
- 6.4.2.3. Competitive Insights
- 6.4.2.4. U.S. Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.4.3. Canada
- 6.4.3.1. Key Country Dynamics
- 6.4.3.2. Regulatory Framework
- 6.4.3.3. Competitive Insights
- 6.4.3.4. Canada Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.4.4. Mexico
- 6.4.4.1. Key Country Dynamics
- 6.4.4.2. Regulatory Framework
- 6.4.4.3. Competitive Insights
- 6.4.4.4. Mexico Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.5. Europe
- 6.5.1. Europe Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 6.5.2. UK
- 6.5.2.1. Key Country Dynamics
- 6.5.2.2. Regulatory Framework
- 6.5.2.3. Competitive Insights
- 6.5.2.4. UK Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.5.3. Germany
- 6.5.3.1. Key Country Dynamics
- 6.5.3.2. Regulatory Framework
- 6.5.3.3. Competitive Insights
- 6.5.3.4. Germany Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.5.4. France
- 6.5.4.1. Key Country Dynamics
- 6.5.4.2. Regulatory Framework
- 6.5.4.3. Competitive Insights
- 6.5.4.4. France Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.5.5. Italy
- 6.5.5.1. Key Country Dynamics
- 6.5.5.2. Regulatory Framework
- 6.5.5.3. Competitive Insights
- 6.5.5.4. Italy Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.5.6. Spain
- 6.5.6.1. Key Country Dynamics
- 6.5.6.2. Regulatory Framework
- 6.5.6.3. Competitive Insights
- 6.5.6.4. Spain Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.5.7. Denmark
- 6.5.7.1. Key Country Dynamics
- 6.5.7.2. Regulatory Framework
- 6.5.7.3. Competitive Insights
- 6.5.7.4. Denmark Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.5.8. Sweden
- 6.5.8.1. Key Country Dynamics
- 6.5.8.2. Regulatory Framework
- 6.5.8.3. Competitive Insights
- 6.5.8.4. Sweden Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 6.5.9. Norway
- 6.5.9.1. Key Country Dynamics
- 6.5.9.2. Regulatory Framework
- 6.5.9.3. Competitive Insights
- 6.5.9.4. Norway Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.6. Asia Pacific
- 6.6.1. Asia Pacific Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.6.2. Japan
- 6.6.2.1. Key Country Dynamics
- 6.6.2.2. Regulatory Framework
- 6.6.2.3. Competitive Insights
- 6.6.2.4. Japan Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.6.3. China
- 6.6.3.1. Key Country Dynamics
- 6.6.3.2. Regulatory Framework
- 6.6.3.3. Competitive Insights
- 6.6.3.4. China Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.6.4. India
- 6.6.4.1. Key Country Dynamics
- 6.6.4.2. Regulatory Framework
- 6.6.4.3. Competitive Insights
- 6.6.4.4. India Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.6.5. Australia
- 6.6.5.1. Key Country Dynamics
- 6.6.5.2. Regulatory Framework
- 6.6.5.3. Competitive Insights
- 6.6.5.4. Australia Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.6.6. Thailand
- 6.6.6.1. Key Country Dynamics
- 6.6.6.2. Regulatory Framework
- 6.6.6.3. Competitive Insights
- 6.6.6.4. Thailand Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.6.7. South Korea
- 6.6.7.1. Key Country Dynamics
- 6.6.7.2. Regulatory Framework
- 6.6.7.3. Competitive Insights
- 6.6.7.4. South Korea Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.7. Latin America
- 6.7.1. Latin America Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 6.7.2. Brazil
- 6.7.2.1. Key Country Dynamics
- 6.7.2.2. Regulatory Framework
- 6.7.2.3. Competitive Insights
- 6.7.2.4. Brazil Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.7.3. Argentina
- 6.7.3.1. Key Country Dynamics
- 6.7.3.2. Regulatory Framework
- 6.7.3.3. Competitive Insights
- 6.7.3.4. Argentina Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.8. MEA
- 6.8.1. MEA Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 6.8.2. South Africa
- 6.8.2.1. Key Country Dynamics
- 6.8.2.2. Regulatory Framework
- 6.8.2.3. Competitive Insights
- 6.8.2.4. South Africa Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.8.3. Saudi Arabia
- 6.8.3.1. Key Country Dynamics
- 6.8.3.2. Regulatory Framework
- 6.8.3.3. Competitive Insights
- 6.8.3.4. Saudi Arabia Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.8.4. UAE
- 6.8.4.1. Key Country Dynamics
- 6.8.4.2. Regulatory Framework
- 6.8.4.3. Competitive Insights
- 6.8.4.4. UAE Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.8.5. Kuwait
- 6.8.5.1. Key Country Dynamics
- 6.8.5.2. Regulatory Framework
- 6.8.5.3. Competitive Insights
- 6.8.5.4. Kuwait Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Participant Overview
- 7.2. Company Market Position Analysis
- 7.3. Company Categorization
- 7.4. Strategy Mapping
- 7.5. Company Profiles/Listing
- 7.5.1. Wuxi Biologics.
- 7.5.1.1. Overview
- 7.5.1.2. Financial Performance
- 7.5.1.3. Product Benchmarking
- 7.5.1.4. Strategic Initiatives
- 7.5.2. FUJIFILM Diosynth Biotechnologies.
- 7.5.2.1. Overview
- 7.5.2.2. Financial Performance
- 7.5.2.3. Product Benchmarking
- 7.5.2.4. Strategic Initiatives
- 7.5.3. Boehringer Ingelheim International GmbH
- 7.5.3.1. Overview
- 7.5.3.2. Financial Performance
- 7.5.3.3. Product Benchmarking
- 7.5.3.4. Strategic Initiatives
- 7.5.4. Lonza
- 7.5.4.1. Overview
- 7.5.4.2. Financial Performance
- 7.5.4.3. Product Benchmarking
- 7.5.4.4. Strategic Initiatives
- 7.5.5. Samsung Biologics
- 7.5.5.1. Overview
- 7.5.5.2. Financial Performance
- 7.5.5.3. Product Benchmarking
- 7.5.5.4. Strategic Initiatives
- 7.5.6. AbbVie Inc.
- 7.5.6.1. Overview
- 7.5.6.2. Financial Performance
- 7.5.6.3. Product Benchmarking
- 7.5.6.4. Strategic Initiatives
- 7.5.7. Catalent
- 7.5.7.1. Overview
- 7.5.7.2. Financial Performance
- 7.5.7.3. Product Benchmarking
- 7.5.7.4. Strategic Initiatives
- 7.5.8. Bioreliance (Merck KGaA)
- 7.5.8.1. Overview
- 7.5.8.2. Financial Performance
- 7.5.8.3. Product Benchmarking
- 7.5.8.4. Strategic Initiatives
- 7.5.9. Thermo Fisher Scientific Inc.
- 7.5.9.1. Overview
- 7.5.9.2. Financial Performance
- 7.5.9.3. Product Benchmarking
- 7.5.9.4. Strategic Initiatives
- 7.5.10. Eurofins Scientific
- 7.5.10.1. Overview
- 7.5.10.2. Financial Performance
- 7.5.10.3. Product Benchmarking
- 7.5.10.4. Strategic Initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook